Drug interactions with antiretroviral agents;Interactions médicamenteuses avec les antirétroviraux

Therapie

Volumn 56, Issue 3, 2001, Pages 267-271

  Furlan, V ^a   Taburet, A M ^a  

^a BICÊTRE HOSPITAL   (France)

Author keywords

Antiretroviral agents; Cytochromes P450; Interaction

Indexed keywords

AMPRENAVIR; ANTIRETROVIRUS AGENT; ASTEMIZOLE; CISAPRIDE; CYTOCHROME P450; CYTOCHROME P450 3A4; EFAVIRENZ; ERGOT DERIVATIVE; INDINAVIR; NEVIRAPINE; RIFAMPICIN; RITONAVIR; SAQUINAVIR;

CONFERENCE PAPER; DRUG ANTAGONISM; DRUG EFFICACY; DRUG METABOLISM; DRUG MONITORING; DRUG POTENTIATION; DRUG TRANSFORMATION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; METHADONE TREATMENT; PRACTICE GUIDELINE; PRIORITY JOURNAL; WITHDRAWAL SYNDROME;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HUMANS; MIXED FUNCTION OXYGENASES; RITONAVIR;

EID: 17344378410     PISSN: 00405957     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (15)

1. Prise en charge thérapeutique des personnes infectées par le VIH. Recommandations du groupe d'experts
2. Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir
3. Interindividual variations in human liver cytochrome P450 enzymes involved in the oxydation of drugs, carcinogens and toxic chemicals: Studies with liver microsomes of 30 Japanese and 30 caucasians
4. Intestinal secretion of drugs. The role of P-glycoprotein and related drug efflux systems in limiting oral drug absorption
5. Pharmacokinetic interactions between two human immunodeficiency virus protease inhibitors, ritonavir and saquinanir
6. Pharmacokinetics and potential interactions amongst antiretroviral agents used to treat patients with HIV infection
7. Therapeutic drug monitoring of amprenavir combined with ritonavir as salvage therapy in HIV-infected patient
8. Indinavir concentrations and St John's wort
9. A potential drug interaction between St John's wort and nevirapine
10. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences
11. Pharmacokinetic interactions between protease inhibitors and selected HMG CoA reductase inhibitors
12. Involvement of cytochrome P450 3A4 enzyme in the N-demethylation of methadone in human liver microsomes
13. Therapeutic drug monitoring of methadone in HIV-infected patients receiving protease inhibitors
14. Cytochrome P450 2B6 (CYP2B6) metabolizes methadone (m) preferentially and stereo-specifically. An explanation of drug interaction with antiretroviral drugs
15. Concomitant human immunodeficiency virus protease inhibitor therapy markedly reduces tacrolimus metabolism and increases blood levels